2009•Chinese Remedies & ClinicsRequires access
In vitro antibacterial activity of Cefotaxime/Tazobactam combination
You Xue-f
Open publisher page 0 citations
Abstract
Objective To investigate the in vitro antibacterial activity of Cefotaxime/Tazobactam combination against β-lactamase-producing Cefotaxime-resistant clinical isolates (MIC≥64 μg/ml). Methods The MICs of different Cefotaxime/Tazobactam combinations (CTX/TAZ 1∶1, 2∶1, 4∶1, 8∶1 and 16∶1) were determined by agar dilution method, and were compared to those of Piperacillin/Tazobactam (8∶1) and Cefoperazone/Sulbactam (1∶1). Results In comparison to Cefotaxime alone, Cefotaxime/Tazobactam showed increased antibacterial activity against β-lactamase-producing E. coli, K. pneumoniae, A. calcoaceticus, E. cloacae, E. aerogenes, S. marcescens and C. diversus. The MIC50s of different Cefotaxime/Tazobactam combinations were 2～64 folds lower than those of Cefotaxime. As to β-lactamase-producing MRSA, MRSE and P. aeruginosa, adding of Tazobactam did not exhibit obvious effects on the antibacterial activity of Cefotaxime, and MIC50s of Cefotaxime/Tazobactam were similar to those of Cefotaxime, or two folds lower. The antibacterial activity of Cefotaxime/Tazobactam combination increased with the amount of Tazobactam in the combination. The MIC50s of Cefotaxime/Tazobactam (4∶1) against E. coli, K. pneumonia, A. calcoaceticus, E. cloacae, E. aerogenes, S. marcescens and C. diversus were 4, 4, 64, 32, 8, 4 and 8 μg/ml respectively, which were 4～32 folds lower than those of Cefotaxime. The antibacterial activities of Cefotaxime/Tazobactam (4∶1) against E. coli and K. penumoniae were 4～8 folds higher than those of Piperacillin/Tazobactam or Cefoperazone/Sulbactam. The antibacterial activities of Cefotaxime/Tazobactam (4∶1) against A. calcoaceticus, E. cloacae, E. aerogenes, S. marcescens and C. diversus were slightly higher than those of Piperacillin/Tazobactam (8∶1), lower or similar to those of Cefoperazone/Sulbactam (1∶1). Conclusion Adding of Tazobactam can effectively increase the antibacterial activities of Cefotaxime against the tested isolates except MRSA, MRSE and P. aeruginosa.